Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026

2026-04-13 03:28:04 ET

The last time I wrote about Voyager Therapeutics ( VYGR ), it was with a Seeking Alpha article entitled " Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects ." With respect to this article, I mentioned that the company was set to provide an update with respect to safety, tolerability, and pharmacokinetic [PK] data from its phase 1 single-ascending dose [SAD] study using its anti-tau monoclonal antibody VY7523 for the treatment of patients with Alzheimer's Disease [AD]. I rated the stock as a "Strong Buy," and I'm going to keep this rating for now. Why is that? Well, there are several reasons why I'm going to maintain this rating for it....

Read the full article on Seeking Alpha

For further details see: